Research programme: hepatitis C virus therapies - Novita Healthcare/CSIRO

Drug Profile

Research programme: hepatitis C virus therapies - Novita Healthcare/CSIRO

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Avexa; CSIRO
  • Developer CSIRO; Novita Healthcare
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-C in Australia
  • 16 Jul 2009 Early research in Hepatitis C in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top